A:NYE-Agilent Technologies Inc.

EQUITY | Medical Diagnostics & Research | New York Stock Exchange

Last Closing

USD 81.2

Change

+0.23 (+0.28)%

Market Cap

USD 14.27B

Volume

1.17M

Analyst Target

USD 85.31
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agilent Technologies Inc provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-19 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing A

TECX:CA TD Global Technology Lead.. 100.34 % 0.00 %

+0.60 (+1.04%)

CAD 2.43M
HHL-U:CA Harvest Healthcare Leader.. 5.25 % 0.00 %

+0.11 (+1.04%)

N/A
HHL:CA Harvest Healthcare Leader.. 5.25 % 1.15 %

+0.13 (+1.04%)

CAD 0.33B
HHL-B:CA Harvest Healthcare Leader.. 5.25 % 0.00 %

+0.15 (+1.04%)

N/A
EDOC Global X Telemedicine & D.. 5.23 % 0.00 %

+0.17 (+1.04%)

USD 0.05B
EDOC:LSE Global X Telemedicine & D.. 5.18 % 0.00 %

+0.27 (+1.04%)

USD 5.32M
EDOG:LSE Global X Telemedicine & D.. 5.18 % 0.00 %

+0.17 (+1.04%)

USD 5.32M
DDOC:F Global X Telemedicine & D.. 4.63 % 0.00 %

+0.05 (+1.04%)

USD 5.32M
EDOC:SW Global X Telemedicine & D.. 4.63 % 0.00 %

+0.21 (+1.04%)

USD 4.92M
GNOG:LSE Global X Genomics & Biote.. 4.57 % 0.00 %

+0.21 (+1.04%)

USD 8.88M
GN0M:XETRA Global X Genomics & Biote.. 4.47 % 0.00 %

+0.22 (+1.04%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.93 % 0.00 %

+0.24 (+1.04%)

USD 6.73M
ABIE:XETRA AXA IM ACT Biodiversity E.. 2.41 % 0.00 %

+0.22 (+1.04%)

N/A
ABIT:XETRA AXA IM ACT Biodiversity E.. 2.29 % 0.00 %

+0.14 (+1.04%)

USD 0.41B
ABIT:F AXA IM ACT Biodiversity E.. 2.29 % 0.00 %

+0.07 (+1.04%)

N/A
ABIE:F AXA IM ACT Biodiversity E.. 2.29 % 0.00 %

+0.12 (+1.04%)

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.09 (+1.04%)

CAD 0.05B
GOAT 0.00 % 0.00 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.14 (+1.04%)

USD 0.10B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+12.00 (+1.04%)

USD 1.14B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

+0.14 (+1.04%)

USD 1.14B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

+0.21 (+1.04%)

USD 5.32M
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

+0.12 (+1.04%)

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

+0.69 (+1.04%)

USD 3.51M

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.37% 41% F 81% B-
Dividend Return N/A N/A N/A N/A F
Total Return 20.37% 41% F 80% B-
Trailing 12 Months  
Capital Gain 17.10% 47% F 89% A-
Dividend Return 0.88% 67% D+ 13% F
Total Return 17.99% 47% F 87% B+
Trailing 5 Years  
Capital Gain 43.39% 29% F 79% B-
Dividend Return 32.30% 86% B+ 86% B+
Total Return 75.69% 43% F 85% B
Average Annual (5 Year Horizon)  
Capital Gain 12.56% 47% F 85% B
Dividend Return 13.11% 41% F 83% B
Total Return 0.55% 43% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 17.99% 47% F 40% F
Risk Adjusted Return 72.88% 35% F 73% C
Market Capitalization 14.27B 76% C+ 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.90 71% 28%
Price/Book Ratio 5.65 24% 12%
Price / Cash Flow Ratio 6.43 41% 15%
Price/Free Cash Flow Ratio 27.90 59% 17%
Management Effectiveness  
Return on Equity 24.28% 82% 87%
Return on Invested Capital 14.46% 76% 72%
Return on Assets 13.17% 88% 93%
Debt to Equity Ratio 40.00% 65% 71%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector